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Abstract: Ketamine is a noncompetitive antagonist of the NMDA-receptors, used as a dissociative anesthetic, presently 
included in the category of the psychoactive substances known as “club drugs”. Ketamine administration was associated 
with impaired working memory and increased psychopathological symptoms, but there is a lack of information regarding 
the effects of chronic sub-anesthetic doses. Adult Wistar rats were administered ketamine, 5 and 10 mg/kg twice daily, 
subcutaneously for 14 days. One week later, rats were tested in an object recognition/object location task and in the open 
field arena. There was altered performance in both the object recognition/location and in the open field tests by the group 
chronically exposed to the lower dose of ketamine. These animals displayed a decreased discrimination index (p<0.05) in 
the object recognition task, were unable to recognize the displacement of a familiar object and displayed decreased activ-
ity across open filed sessions. Importantly, these alterations were not observed in animals administered a higher dose of 
ketamine. Collectively, these results consistently show that chronic administration of ketamine in sub-anesthetic doses 
may lead to decreased habituation and inability to update spatial representations. 
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INTRODUCTION 
  Ketamine is a clinically and veterinary important drug 
commonly used in anesthesia and perioperative analgesia [1, 
2]. It’s psychedelic properties make it also a popular drug of 
abuse [3]. At subanesthetic doses, the role of ketamine, as a 
noncompetitive  N-methyl-D-aspartate (NMDA) receptor 
antagonist, in blocking the processing of nociceptive inputs 
has led to its use in chronic pain syndromes management   
[4, 5]. However, ketamine use, both in preclinical studies   
[6] or in compulsive users was reported to induce cognitive 
impairments [7]. 
  Acute subanesthetic doses of ketamine were shown to 
induce a marked increase in glutamate release in the nucleus 
accumbens facilitating synaptic flow of information from the 
prefrontal cortex (PFC) and amygdala [8], which is consistent 
with the hypothesis that ketamine acts preferentially to block 
NMDA receptors on inhibitory neurons leading to a state of 
disinhibition and increased glutamate release in the PFC and 
limbic regions [8, 9]. Importantly, the administration of chronic 
and sub-chronic doses of other NMDA antagonists lead to 
disruption of the hippocampal and PFC function [10-12], 
Particularly, chronic NMDA-antagonism, has been reported 
to induce persistent deficits in working memory [10, 13, 14].  
  With regards to the chronic action of ketamine, inconsis-
tent results have been reported, which seem to reflect differ-
ent treatment protocols and evaluation schedules. Therefore, 
the purpose of the present study was to contribute to the 
clarification of the long term effects of chronic analgesic   
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doses of ketamine in memory disruption. To achieve this 
goal the object recognition test and object location task   
were selected to assess, respectively, spatial and non-spatial 
recognition memory. Locomotor activity and the ability to 
habituate to a new environment were also monitored. 
MATERIALS AND METHODS 
Animals 
  Male Wistar rats (colony of the Institute of Molecular 
and Cell Biology, University of Porto, Portugal) aged 80 to 
90 days were used. Rats were housed in pairs in a controlled 
environment (20±2ºC, 45-55% humidity) with 12-h light/ 
dark cycle. Food and water were supplied “ad libitum”.   
All experiments were approved by the Portuguese Agency 
for Animal Welfare (general board of Veterinary Medicine 
in compliance with the Institutional Guidelines and the   
European Convention). 
  Rats were divided in 3 experimental groups as follows: 
ketamine 5 mg/kg every 12 hours (K 5mg), ketamine 10 
mg/kg every 12 hours (K 10mg) and saline or control (vehi-
cle Nacl 9%) in the same administration protocol. The se-
lected doses were shown to be analgesic in previous studies 
[15, 16]. Ketamine (Imalgene 1000, Merial Portuguesa) was 
administered subcutaneously (s.c.), in 12 h intervals, in a 
volume of 1 ml/kg of body weight, for 14 consecutive days. 
All behavioral experiments were performed during the dark 
period of light cycle and video recorded. Behavioural data 
were subsequently analysed using the software Observer XT 
(Noldus Information Technology, Wageningen, Netherlands). 
  The object recognition  test was performed as describe 
previously [17]. Briefly, the test apparatus consisted in a 
grey open box made of PVC (60 x 80 x 40 cm).The objects 
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shapes: cubes, pyramids and cylinders. Twenty four hours 
after the last administration of ketamine, rats were allowed to 
explore the apparatus, for 10 min, with a single object (fa-
miliar object) placed in the center of the open box. This was 
repeated for 5 consecutive days. The object recognition test 
began after the habituation period. Initially, a sample phase 
with two identical objects placed in two opposite corners of 
apparatus (10 cm from the side wall) was utilized. The rat 
was placed in the middle of the apparatus, allowed to explore 
these objects for 3 min and then returned to its home cage. 
Choice phases were conducted with both a delay of 15 min 
and a delay of 24 hours. The rat was reintroduced into the 
open box and a choice phase took place for further 3 min. In 
the choice phase two objects were exposed in the same loca-
tions that were occupied by objects in the previous sample 
phase, one of the objects was identical to those presented in 
the sample phase and the other was a novel object. The time 
spent exploring each object was recorded. Exploration was 
defined as follows: rat touches the object with its nose or the 
rat’s nose is directed toward the object at a distance shorter 
than 2 cm. Circling or sitting on the object were not consid-
ered as exploratory behaviors. The index of discrimination 
was calculated as the difference between contact time with 
the novel and the familiar object [17]. 
  Object location testing was conducted 24 h after the ob-
ject recognition test. This test is similar to the object recogni-
tion task described above, except for the choice phase test, 
where the two identical objects are re-exposed, but one of 
them is moved to a novel location. In the object location 
task, only a delay of 15 min was evaluated. 
  One week after the last ketamine administration locomo-
tor activity was evaluated by placing a single rat into an 
acrylic cubic open field arena (40 x 40 x 40 cm), equipped 
with two parallel arrays of photocells (San Diego Instru-
ments, San Diego, CA). Data were collected in 1 min inter-
vals over 10 minute’s sessions. Each rat was tested for three 
consecutive days. The following parameters were automati-
cally registered: rearing, central activity, peripheral activity 
(i.e. frequency of locomotion along the walls of the open-
field). Habituation to the open-field environment was also 
studied by comparing the total locomotor activity across 
open-field sessions. 
  Data were analysed by repeated-measures analysis of 
variance (ANOVA). Whenever significant differences were 
detected, further comparisons were made using the Student`s 
t-test. In addition, Paired-samples t-test was performed on 
individual groups to examine whether animals demonstrated 
preference for novelty. Habituation between sessions was 
also analyzed by Paired-samples t–test. The statistical level 
of significance was considered at p<0.05. Statistic analyses 
were performed using the software SPSS Statistics 17 (SPSS 
Inc., IL).  
RESULTS AND DISCUSSION 
  Body weight gain was monitored throughout the experi-
mental period. A chronic ketamine administration at the 
doses of 5 (K 5mg) and 10 mg/kg (K 10mg) decreased the 
evolution of body weight as shown in “Fig. (1)”. Two days 
after the onset of the experimental period, weight gain values 
in the ketamine treated groups were significantly reduced. 
This effect persisted after the end of ketamine administration 
period and throughout the behavioural testing phase. Inter-
estingly, these data are not in accordance with previous re-
ports where a chronic administration (7 days) of ketamine 15 
mg/kg (i.p) was shown to increase body weight and sweet 
food consumption [18]. However, humans chronically ad-
ministered with low doses of ketamine reported side effects 
such as nausea and vomiting with consequent loss of appetite 
[19]. Moreover, ketamine is known to interfere with gusta-
tory trace in a dose dependent manner [20], which can also 
account for reduced food intake. 
 
 
 
 
 
 
 
 
Fig. (1). Decreased body weight gain. Weight gain throughout the 
experimental period for the three groups of rats under study: saline 
(n=18), K 5mg (ketamine 5 mg/kg, n=17) and K 10mg (ketamine 
10 mg/kg, n=17). Each point represents the mean ± standard error 
of body weight in a given day. Since day 3, animals treated with 
either dose of ketamine displayed significantly decreased weight 
gain as determined by the Turkey HSD for unequal N test. The 
arrow indicates the end of the administration period. 
  Results obtained in the object recognition task show that 
all experimental groups preferentially explored the unfamil-
iar object, either when the new object was presented 15 min 
after the presentation session, or when it was presented with 
a delay of 24h. These results are shown in “Fig. (2)”. Re-
garding the discrimination based on the duration of explora-
tion, all the groups presented a positive discrimination index 
between the familiar and unfamiliar object both in the short-
term and long-term delay, since all of them spent more time 
exploring the unfamiliar object “Fig. (3)”. However, when 
discrimination was evaluated based on the time spent explor-
ing the unfamiliar object, the animals treated with the lower 
dose of ketamine displayed a decreased discrimination index 
(p<0.05). Interestingly, this seems to be caused by increased 
exploration of the familiar object and to some extent may 
reflect altered habituation properties. Habituation is a com-
plex function; however, the relevance of the hippocampus in 
this process is well established. In rodents, habituation may 
be seen as a decreased exploratory behaviour in response to 
continued or repeated environment or stimulus [21]. Fur-
thermore, habituation is commonly used for assessment of 
non-associative learning and memory processes. Glutamate 
is known to facilitate memory retention, while NMDA an-
tagonists were shown to decrease habituation in a dose de-
pendent manner [22]. It was reported that MK-801 admini-
stration did not interfere with the ability to recognize a novel 
object but prevented the correct identification of spatial 
changes, suggesting that NMDA blockade may result in in-
ability to update spatial representations [23].  Ketamine Impaired Spatial Memory  Current Neuropharmacology, 2011, Vol. 9, No. 1    253 
  Importantly, in the object location task, while the control 
animals and the group treated with a higher dose of ketamine 
(10 mg K) were able to distinguish between a familiar object 
in a familiar location, and an equal object in a novel location 
(p<0.01 and p<0.05, respectively); the animals treated with a 
lower dose of ketamine (5 mg K) were unable recognize the 
displacement “Fig. (4)”. These results reinforce the inability 
presented by the animals chronically treated with 5 mg of 
ketamine, to display an adequate habituation, which can re-
sult from altered glutamatergic function. Spatial processing 
has been shown to relate with infra pyramidal mossy fibber 
terminals that form glutamatergic synaptic contacts on com-
plex branching spines [24]. Although, at the synaptic level, 
electrophysiological and imaging studies suggested a 
stronger involvement of AMPA receptors than NMDA re-
ceptors [25, 26], it was shown that blocking both types of 
receptors would alter the formation of clusters at the terminal 
level, which would translate into altered hippocampal func-
tion [27]. 
  In the open field, while total or locomotor activity was 
not affected by ketamine, the group treated with 5 mg of 
ketamine failed to reduce activity across sessions “Fig. (5)”. 
In the open field, rodents habituation was evaluated by de-
clined activity through consecutive daily sessions [21]. In the 
present work, only controls and animals treated with 10 mg 
of ketamine displayed this adaptation (p<0.05 and p<0.001, 
respectively). In accordance with what was observed in the 
object recognition/location task, these results also point to-
wards impaired habituation in animals chronically adminis-
trated with 5 mg of ketamine and may be a consequence of 
disrupted spatial memory. This is in agreement with previous 
reports were a single administration of very low doses of 
ketamine (1 and 3 mg /Kg) was shown to impair spatial 
memory in an object location test [28]. Recently, in rats 
treated for 10 days with 30 mg/Kg of ketamine (twice a day) 
and tested in a radial maze 10 to 20 days after cessation of 
treatment, a persistent impairment of spatial working mem-
ory was observed and associated to altered function of the 
 
 
 
 
 
 
 
 
Fig. (2). Time spent exploring the familiar and unfamiliar objects in the choice phase of the object recognition task, using both a 15 min and 
a 24 h delay. Male Wistar rats were treated with 5 mg/kg of ketamine (K 5mg, n=9) and 10 mg/kg of ketamine (K 10mg, n=9), in 12 h inter-
vals. The control group received an isovolumetric dose of saline solution following the same protocol (Saline, n=10). Results were repre-
sented as the mean + standard error for each group (expressed as time in sec). Significant differences were signed as p<0.01 or 
p<0.001. 
 
 
 
 
 
 
 
 
 
Fig. (3). Effects of chronic ketamine administration on discrimination index performance, determined as the difference between the time 
spent exploring the novel object and the familiar, after both a 15 min and a 24 h delay. Male Wistar rats were treated with 5 mg/kg of keta-
mine (K 5mg, n=9) and 10mg/kg of ketamine (K 10mg, n=9), in 12 h intervals. The control group received an isovolumetric dose of saline 
solution following the same protocol (Saline, n=10). Results were represented as the mean + standard error for each group (expressed as time 
in sec). Significant differences were signed as  p<0.05. 254    Current Neuropharmacology, 2011, Vol. 9, No. 1  Venâncio et al. 
prefrontal cortex but not the hippocampus [14]. However, in 
that study, rats were trained before exposure to ketamine and 
therefore acquisition and consolidation of spatial/contextual 
information was achieved prior to NMDA antagonism. 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Time spent exploring objects placed in familiar or unfamil-
iar locations in the choice phase of the object location task, using a 
15 min delay. Male Wistar rats were treated with 5 mg/kg of keta-
mine (K 5mg, n=9) and 10mg/kg of ketamine (K 10mg, n=9), in 12 
h intervals. The control group received an isovolumetric dose of 
saline solution following the same protocol (Saline, n=10). Results 
were represented as the mean ± standard error for each group (ex-
pressed as time in seconds). Significant differences were signed as 
p<0.05 or  p<0.01. 
 
 
 
 
 
 
 
 
Fig. (5). Effects of chronic administration of ketamine on total ac-
tivity and habituation into the open-field arena. Male Wistar rats 
were treated with 5 mg/kg of ketamine and 10mg/kg of ketamine (K 
10mg, n=9), in 12 h intervals. The control group received an iso-
volumetric dose of saline solution following the same protocol (Sa-
line, n=10). The results were represented as the mean ± standard 
error (expressed as counts in 10 min sessions). Significant differ-
ences were signed as p<0.05 or p<0.001. 
  Another interesting aspect of the present results is the 
consistent difference observed between the effects of a 5 
mg/Kg dose and a 10 mg/Kg dose. Although the molecular 
mechanisms that underlie the present results remain unclear, 
a previous study, that investigated the dose-response charac-
teristics of ketamine, has shown that a 4 mg/Kg dose was 
able to induce a much higher expression of c-fos in the hip-
pocampus and amygdalar regions, than doses of 8, 12 or 16 
mg/Kg [6]. It was proposed that this dose-effect could be due 
to the indirect activation of excitatory neurotransmitter sys-
tems, as a consequence of reduced activity of GABAergic 
neurons under low doses of NMDA antagonists [6]. Impor-
tantly, the glutamatergic afferents from the hippocampus and 
the amygdala provide a gating of information flow into the 
prefrontal cortex [29] and increased expression of c-fos in 
these regions is likely to be associated with altered cognitive 
function. 
  In summary, viewed collectively, the present results pro-
vide consistent evidence of inability to update spatial repre-
sentations and decreased habituation properties, induced by 
chronic treatment with sub-anesthetic doses of ketamine. 
This is particularly relevant for the use of ketamine in the 
analgesia in chronic-pain syndromes. 
ACKNOWLEDGEMENT 
  This work was financed by program COMPETE – FCT 
PTDC/CVT/099022/2008 and Programa Plurianual do IBMC. 
Carlos Venâncio (SFRH/BD/38-907/2007) and Ana Magalhães 
(SFRH/BPD/19200/2004) were granted by Fundação para a 
Ciência e Tecnologia (FCT). 
REFERENCES 
[1]  Annetta, M.G., Iemma, D., Garisto, C., Tafani, C., Proietti, R. 
Ketamine: new indications for an old drug. Curr. Drug Targets, 
2005, 6, 789-794. 
[2]  Ueyama, Y., Waselau, A.C., Wiese, A.J., Muir, W.W. Anesthetic 
and cardiopulmonary effects of intramuscular morphine, mede-
tomidine, ketamine injection in dogs. Vet. Anaesth. Analg., 2008, 
35, 480-487. 
[3]  Muetzelfeldt, L., Kamboj, S.K., Rees, H., Taylor, J., Morgan, C.J., 
Curran, H.V. Journey through the K-hole: phenomenological as-
pects of ketamine use. Drug Alcohol Depend., 2008, 95, 219-229. 
[4]  Bell, R.F. Ketamine for chronic non-cancer pain. Pain, 2009, 141, 
210-214. 
[5]  Hocking, G., Cousins, M.J. Ketamine in chronic pain management: 
an evidence-based review. Anesth. Analg., 2003, 97, 1730-1739. 
[6]  Imre, G., Fokkema, D.S., Den Boer, J.A., Ter Horst, G.J. Dose-
response characteristics of ketamine effect on locomotion,   
cognitive function and central neuronal activity. Brain Res. Bull., 
2006, 69, 338-345. 
[7]  Morgan, C.J., Muetzelfeldt, L., Curran, H.V. Ketamine use, cogni-
tion and psychological wellbeing: a comparison of frequent, infre-
quent and ex-users with polydrug and non-using controls. Addic-
tion, 2009, 104, 77-87. 
[8]  Razoux, F., Garcia, R., Lena, I. Ketamine, at a dose that disrupts 
motor behavior and latent inhibition, enhances prefrontal cortex 
synaptic efficacy and glutamate release in the nucleus accumbens. 
Neuropsychopharmacology, 2007, 32, 719-727. 
[9]  Holcomb, H.H., Lahti, A.C., Medoff, D.R., Cullen, T., Tamminga, 
C.A. Effects of noncompetitive NMDA receptor blockade on ante-
rior cingulate cerebral blood flow in volunteers with schizophrenia. 
Neuropsychopharmacology, 2005, 30, 2275-2282. 
[10]  Enomoto, T., Floresco, S.B. Disruptions in spatial working   
memory, but not short-term memory, induced by repeated ketamine 
exposure.  Prog. Neuropsychopharmacol. Biol. Psychiatry,  2009, 
33, 668-675. 
[11]  Lewis, D.A., Gonzalez-Burgos, G. Neuroplasticity of neocortical 
circuits in schizophrenia. Neuropsychopharmacology,  2008,  33, 
141-165. 
[12]  Pratt, J.A., Winchester, C., Egerton, A., Cochran, S.M., Morris, 
B.J. Modelling prefrontal cortex deficits in schizophrenia: implica-
tions for treatment. Br. J. Pharmacol., 2008, 153(Suppl 1), S465-
470. 
[13]  Beraki, S., Diaz-Heijtz, R., Tai, F., Ogren, S.O. Effects of repeated 
treatment of phencyclidine on cognition and gene expression in 
C57BL/6 mice. Int. J. Neuropsychopharmacol., 2009, 12, 243-255. 
[14]  Marquis, J.P., Killcross, S., Haddon, J.E. Inactivation of the pre-
limbic, but not infralimbic, prefrontal cortex impairs the contextual 
control of response conflict in rats. Eur. J. Neurosci., 2007,  25, 
559-566. Ketamine Impaired Spatial Memory  Current Neuropharmacology, 2011, Vol. 9, No. 1    255 
[15]  Meen, M., Coudore-Civiale, M.A., Parry, L., Eschalier, A., 
Boucher, M. Involvement of N-methyl-D-aspartate receptors in   
nociception in the cyclophosphamide-induced vesical pain model 
in the conscious rat. Eur. J. Pain, 2002, 6, 307-314. 
[16]  Pelissier, T., Alvarez, P., Hernandez, A. Effect of long-term keta-
mine administration on vocalization to paw pressure and on spinal 
wind-up activity in monoarthritic rats. Int. J. Neurosci., 2003, 113, 
1305-1313. 
[17]  Ennaceur, A., Michalikova, S., Bradford, A., Ahmed, S. Detailed 
analysis of the behavior of Lister and Wistar rats in anxiety, object 
recognition and object location tasks. Behav. Brain Res., 2005, 159, 
247-266. 
[18]  Gracia, L. S., Comim, C.M., Valvassori, S.S., Reurs, G.Z., Stertz, 
L., Kapczinski, F., Gavioli, E.C., Quevedo, J. Ketamine treatment 
reverses behavioral and Physiological alterations induced by 
chronic mild stress in rats. Prog. Neuropsychopharmacol. Biol. 
Psychiatry, 2009, 33, 450-455. 
[19]  Cvrcek, P. Side effects of ketamine in the long-term treatment of 
neuropathic pain. Pain Med., 2008, 9, 253-257. 
[20]  Traverso, L.M., Ruiz, G., Camino, G., De la Casa, L.G. Ketamine 
blocks the formation of a gustatory memory trace in rats. Pharma-
col. Biochem. Behav., 2008, 90, 305-311. 
[21]  Leussis, M.P., Bolivar, V.J. Habituation in rodents: a review of 
behavior, neurobiology, and genetics. Neurosci. Biobehav. Rev., 
2006, 30, 1045-1064. 
[22]  Rosat, R., Da-Silva, R.C., Zanatta, M.S., Medina, J.H., Izquierdo, I. 
Memory consolidation of a habituation task: role of N-methyl-D-
aspartate, cholinergic muscarinic and GABA-A receptors in differ-
ent brain regions. Braz. J. Med. Biol. Res., 1992, 25, 267-273. 
[23]  Roullet, P., Mele, A., Ammassari-Teule, M. Involvement of gluta-
matergic and dopaminergic systems in the reactivity of mice to spa-
tial and non-spatial change. Psychopharmacology (Berl), 1996, 
126, 55-61. 
  [24]  Cerbone, A., Patacchioli, F.R., Sadile, A.G. A neurogenetic and 
morphogenetic approach to hippocampal functions based on indi-
vidual differences and neurobehavioral covariations. Behav. Brain 
Res., 1993, 55, 1-16. 
[25]  Henze, D.A., Urban, N.N., Barrionuevo, G. The multifarious hip-
pocampal mossy fiber pathway: a review. Neuroscience, 2000, 98, 
407-427. 
[26]  Reid, C.A., Fabian-Fine, R., Fine, A. Postsynaptic calcium tran-
sients evoked by activation of individual hippocampal mossy fiber 
synapses. J. Neurosci., 2001, 21, 2206-2214. 
[27]  Qin, L., Marrs, G.S., McKim, R., Dailey, M.E. Hippocampal mossy 
fibers induce assembly and clustering of PSD95-containing post-
synaptic densities independent of glutamate receptor activation. J. 
Comp. Neurol., 2001, 440, 284-298. 
[28]  Pitsikas, N., Boultadakis, A., Sakellaridis, N. Effects of sub-
anesthetic doses of ketamine on rats' spatial and non-spatial recog-
nition memory. Neuroscience, 2008, 154, 454-460. 
[29]  Grace, A.A. Gating of information flow within the limbic system 
and the pathophysiology of schizophrenia. Brain Res. Brain Res. 
Rev., 2000, 31, 330-341. 
 
 
Received: October 01, 2009  Revised: April 17, 2010  Accepted: May 26, 2010 
 
 